Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX

Document Type

Journal Article

Publication Date

5-4-2017

Journal

Expert Review of Clinical Pharmacology

Volume

10

Issue

5

DOI

10.1080/17512433.2017.1302330

Keywords

FOLFIRINOX; gemcitabine; healthcare costs; healthcare utilization; metastatic pancreatic cancer; nab-paclitaxel

Abstract

© 2017 Informa UK Limited, trading as Taylor & Francis Group. Background: We compared real-world treatment patterns, resource utilization, and cost of care for patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel + gemcitabine or FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin). Methods: This was a retrospective study of inpatient and hospital-based outpatient data in the United States. Primary endpoints included median time to treatment discontinuation (TTD) and total cost of care per patient per month. Secondary endpoints included supportive care costs and hospitalization rate and length. Results: Overall, 345 patients were included (nab-paclitaxel + gemcitabine, n = 182; FOLFIRINOX, n = 163). Median TTD was significantly longer with nab-paclitaxel + gemcitabine vs FOLFIRINOX (4.3 vs 2.8 months; P =.0009). Mean acquisition cost was higher with nab-paclitaxel + gemcitabine ($10,643 vs $6549; P =.0043), but mean total cost of care was lower ($16,628 vs $19,936; P =.1740). Supportive care cost was significantly lower with nab-paclitaxel + gemcitabine ($1995 vs $6456; P <.0001). Hospitalization rate and length were both significantly lower with nab-paclitaxel + gemcitabine. Conclusions: Despite higher acquisition costs with nab-paclitaxel + gemcitabine, FOLFIRINOX-treated patients had higher total costs driven by supportive care. Toxicity-related costs and drug acquisition costs should be considered when evaluating total cost of care.

Link to Full Text

Share

COinS